Carey et al discovered that adding lapatinib to trastuzumab in addition to paclitaxel routine fundamentally improved the disease-free survival in breast cancer patients with HER2-positive.16Lapatinib monotherapy or in combination with capecitabine was found viable in patients with p95HER2-negative, HER2-positive, and p95HER2-positive cases of breast tumors.17In another review, lapatinib mixed with capecitabine was determined as a functioning treatment choice for women with HER2-positive MBC, incorporating those with moderate central nervous system (CNS) disease.18 The gene discussed is ERBB2; the disease is breast carcinoma.